Syngene Introduces Innovative Platform for Quick and Enhanced Protein Production
Wednesday, June 05, 2024
Syngene International Ltd. (NSE: SYNGENE) has recently introduced its latest protein production platform, integrating cell line and transposon-based technology from ExcellGene, a Swiss biotech services company, with its own clone selection and development processes. This novel approach promises significant advancements in efficiency and precision in protein production.
This new platform aims to expedite preclinical and clinical development cycles and accelerate product launches, ultimately reducing time to market for clients. Sridevi Khambhampaty, Vice President of Biopharmaceutical Development at Syngene International, highlighted the benefits of combining ExcellGene's technology with Syngene's processes, emphasizing its potential to enhance reliability and efficiency.
Syngene International, emphasized the company's commitment to leveraging cutting-edge technology to ensure speed and precision for clients, particularly in the biologics sector. Maria J. and Florian M. Wurm, Cofounders and Managers of ExcellGene, expressed their excitement about the partnership with Syngene and its potential to benefit a wide range of clients.
The new platform not only improves clone selection and operational productivity but also accommodates various biomolecules, facilitating integration with different manufacturing processes. Its effectiveness is demonstrated by its successful track record in developing multiple monoclonal antibodies, showcasing Syngene's capability to provide innovative solutions to its clients.
With this advancement, Syngene now offers a comprehensive range of cell line development options, utilizing state-of-the-art technology to deliver tangible benefits to customers.
Source: prnewswire.com
